COVID-19 mRNA疫苗接种后与突破性感染相关的癌症类型和基因特征

IF 6.9 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2025-05-09 DOI:10.1038/s41541-025-01141-w

Youjia Zhong, Jiaqi Li, Ainsley Ryan Yan Bin Lee, Janice Yu Jin Tan, Carina Jing Xuan Tay, Clara Wt Koh, Ethan Yong Tzi Seow, Wee Chee Yap, Shi Yin Wong, Chun En Yau, Chen Ee Low, Kelvin Bryan Tan, Barnaby Edward Young, Yan Su, Arun George Devasia, Perumal Dharuman, Alexander Lezhava, Rahul Pandey, Panneer Selvi Govindaraju, Sidney Yee, Ruifen Weng, Candy Khoo, Shaun Shi Yan Tan, Matilda Lee, Joline Lim, Esther Chan, Carol Lf Ho, Louis Yi Ann Chai, Chee Wah Tan, Soo Chin Lee, Kuan Rong Chan, Raghav Sundar

{"title":"COVID-19 mRNA疫苗接种后与突破性感染相关的癌症类型和基因特征","authors":"Youjia Zhong, Jiaqi Li, Ainsley Ryan Yan Bin Lee, Janice Yu Jin Tan, Carina Jing Xuan Tay, Clara Wt Koh, Ethan Yong Tzi Seow, Wee Chee Yap, Shi Yin Wong, Chun En Yau, Chen Ee Low, Kelvin Bryan Tan, Barnaby Edward Young, Yan Su, Arun George Devasia, Perumal Dharuman, Alexander Lezhava, Rahul Pandey, Panneer Selvi Govindaraju, Sidney Yee, Ruifen Weng, Candy Khoo, Shaun Shi Yan Tan, Matilda Lee, Joline Lim, Esther Chan, Carol Lf Ho, Louis Yi Ann Chai, Chee Wah Tan, Soo Chin Lee, Kuan Rong Chan, Raghav Sundar","doi":"10.1038/s41541-025-01141-w","DOIUrl":null,"url":null,"abstract":"We used epidemiological data from 21195 patients with cancer and 180407 matched controls, including in-depth analyses in 216 cancer patients, to discover clinical and molecular determinants that predispose cancer patients to breakthrough infections. Patients with B cell malignancies, with differential expression of CD24, CDK14 and PLEKHG1, were most susceptible to breakthrough infections, suggesting that these patients may require more booster immunisations to ameliorate cellular responses and immune protection against COVID-19.","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"90"},"PeriodicalIF":6.9000,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062431/pdf/","citationCount":"0","resultStr":"{\"title\":\"Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination.\",\"authors\":\"Youjia Zhong, Jiaqi Li, Ainsley Ryan Yan Bin Lee, Janice Yu Jin Tan, Carina Jing Xuan Tay, Clara Wt Koh, Ethan Yong Tzi Seow, Wee Chee Yap, Shi Yin Wong, Chun En Yau, Chen Ee Low, Kelvin Bryan Tan, Barnaby Edward Young, Yan Su, Arun George Devasia, Perumal Dharuman, Alexander Lezhava, Rahul Pandey, Panneer Selvi Govindaraju, Sidney Yee, Ruifen Weng, Candy Khoo, Shaun Shi Yan Tan, Matilda Lee, Joline Lim, Esther Chan, Carol Lf Ho, Louis Yi Ann Chai, Chee Wah Tan, Soo Chin Lee, Kuan Rong Chan, Raghav Sundar\",\"doi\":\"10.1038/s41541-025-01141-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"We used epidemiological data from 21195 patients with cancer and 180407 matched controls, including in-depth analyses in 216 cancer patients, to discover clinical and molecular determinants that predispose cancer patients to breakthrough infections. Patients with B cell malignancies, with differential expression of CD24, CDK14 and PLEKHG1, were most susceptible to breakthrough infections, suggesting that these patients may require more booster immunisations to ameliorate cellular responses and immune protection against COVID-19.\",\"PeriodicalId\":19335,\"journal\":{\"name\":\"NPJ Vaccines\",\"volume\":\"10 1\",\"pages\":\"90\"},\"PeriodicalIF\":6.9000,\"publicationDate\":\"2025-05-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062431/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NPJ Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41541-025-01141-w\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-025-01141-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

我们使用了来自21195名癌症患者和180407名匹配对照的流行病学数据，包括对216名癌症患者的深入分析，以发现癌症患者易受突破性感染的临床和分子决定因素。CD24、CDK14和PLEKHG1表达差异的B细胞恶性肿瘤患者最容易发生突破性感染，这表明这些患者可能需要更多的强化免疫来改善细胞反应和对COVID-19的免疫保护。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Cancer type and gene signatures associated with breakthrough infections following COVID-19 mRNA vaccination.

We used epidemiological data from 21195 patients with cancer and 180407 matched controls, including in-depth analyses in 216 cancer patients, to discover clinical and molecular determinants that predispose cancer patients to breakthrough infections. Patients with B cell malignancies, with differential expression of CD24, CDK14 and PLEKHG1, were most susceptible to breakthrough infections, suggesting that these patients may require more booster immunisations to ameliorate cellular responses and immune protection against COVID-19.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.